Carri Duncan
Senior Advisor
She/Her
Life at FGS Global
Focus on healthcare, strategy and transformation topics.
Advises companies on capital markets situations, issues management and strategic communications to help businesses navigate through critical phases.
Life Pre-FGS Global
Combined science, finance and corporate leadership topics. Former research scientist. Provided advisory to C-suites on strategy, IR and M&A at global banks and Pharma companies and as co-founder at Karaktero. As Partner at Brunswick, focused on Healthcare and financial transactions.
Life Beyond FGS Global
Former beekeeper and life-long learner/explorer. Enjoys family time at home. Emerging technology trends and startups also a passion. Can spontaneously share fun facts about her hometown, Detroit.
Carri Duncan advises leaders across the healthcare ecosystem, from global life sciences companies to institutional investors. Her career spans science, finance, and corporate leadership, giving her a unique perspective on the complex challenges faced by organizations shaping and investing in healthcare.
Her journey began in biomedical research, conducting work in academic institutions and at Novartis that contributed to peer-reviewed publications. Carri transitioned to capital markets, playing a pivotal role in establishing buy-side biotech coverage at Credit Suisse before serving as a sell-side analyst at Sal Oppenheim/Macquarie. From 2014 to 2018, she was VP of Investor Relations at Bayer, where she advised the board on capital markets strategy, expanded the company’s geographical shareholder base, and co-conceptualized LEAPS, Bayer’s venture arm for breakthrough innovation.
Carri co-founded Karaktero to support healthcare companies and funds on strategy, partnering and communications. Previously a healthcare partner at Brunswick, she now serves as European Healthcare Sector Lead at FGS Global, supporting senior executives, boards, and key ecosystem stakeholders through high-impact situations. Her expertise includes crisis communications, capital markets narratives, and corporate transformation.
Carri is a molecular and cell biologist by training and holds a PhD in Neuroscience from ETH-Zürich.
